Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 282-288, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pandian, M. R.
Right arrow Articles by Segre, G. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pandian, M. R.
Right arrow Articles by Segre, G. V.

Clinical Chemistry, Vol 38, 282-288, Copyright © 1992 by American Association for Clinical Chemistry

Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia

MR Pandian, CH Morgan, E Carlton and GV Segre
Nichols Institute, San Juan Capistrano, CA 92675.

We have developed a sensitive, specific solid-phase immunoradiometric assay (IRMA) of parathyroid hormone-related protein (PTH-RP) with use of affinity-purified polyclonal immunoglobulins. Antibodies recognizing PTH-RP(37-74) are immobilized to a polystyrene bead to "capture" analytes from the sample; antibodies to epitopes within the 1-36 amino acid region of PTH-RP are labeled with 125I. This IRMA recognizes PTH- RP(1-74) and PTH-RP(1-86) equivalently, but does not detect N-terminal or C-terminal fragments of PTH-RP, intact human parathyrin (PTH), or fragments of PTH. PTH-RP is not stable in plasma at 3-5 degrees C or room temperature, but a mixture of aprotinin (500 kallikrein units/L) and leupeptin (2.5 mg/L) improves PTH-RP stability in blood samples. In plasma collected in the presence of these protease inhibitors from normal volunteers and patients with various disorders of calcium metabolism, PTH-RP concentrations were above normal (greater than 1.5 pmol/L) in 91% (42 of 46) of patients with hypercalcemia associated with nonhematological malignancy. In plasma from patients with other hypercalcemic conditions (e.g., primary hyperparathyroidism, sarcoidosis, and vitamin D excess), PTH-RP was undetectable. Above- normal concentrations of PTH-RP and total calcium decreased to normal in a patient with an ovarian cyst adenocarcinoma after surgical removal of the tumor. We conclude that PTH-RP is related to and probably the causative agent of hypercalcemia in most patients with cancer, and that measurements of PTH-RP are useful in the diagnosis and management of patients with tumor-associated hypercalcemia.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. Rej
Clinical Chemistry through Clinical Chemistry: A Journal Timeline
Clin. Chem., December 1, 2004; 50(12): 2415 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Francini, A. Scardino, K. Kosmatopoulos, F. A. Lemonnier, G. Campoccia, M. Sabatino, D. Pozzessere, R. Petrioli, L. Lozzi, P. Neri, et al.
High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects
J. Immunol., November 1, 2002; 169(9): 4840 - 4849.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Bendre, D. Gaddy-Kurten, T. Mon-Foote, N. S. Akel, R. A. Skinner, R. W. Nicholas, and L. J. Suva
Expression of Interleukin 8 and not Parathyroid Hormone-related Protein by Human Breast Cancer Cells Correlates with Bone Metastasis in Vivo
Cancer Res., October 1, 2002; 62(19): 5571 - 5579.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Rizzoli, D. Thiebaud, N. Bundred, M. Pecherstorfer, Z. Herrmann, H. J. Huss, F. Ruckert, C. Manegold, M. Tubiana-Hulin, E. U. Steinhauer, et al.
Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3545 - 3550.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. J. Thomas, T. A. Guise, J. J. Yin, J. Elliott, N. J. Horwood, T. J. Martin, and M. T. Gillespie
Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation
Endocrinology, October 1, 1999; 140(10): 4451 - 4458.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
T. A. Guise and G. R. Mundy
Cancer and Bone
Endocr. Rev., February 1, 1998; 19(1): 18 - 54.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Gorai, Y. Taguchi, O. Chaki, R. K. M. Nakayama, B. C. Yang, S. Yokota, and H. Minaguchi
Serum Soluble Interleukin-6 Receptor and Biochemical Markers of Bone Metabolism Show Significant Variations During the Menstrual Cycle
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 326 - 332.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.